文献速递糖尿病肥胖与代谢综合征

从DPP-4抑制剂转换为口服司美格鲁肽后β细胞功能的改善:SWITCH-SEMA2事后分析

Improvement of β-Cell Function After Switching From DPP-4 Inhibitors to Oral Semaglutide: SWITCH-SEMA2 Post Hoc Analysis.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

SWITCH-SEMA2多中心前瞻性随机对照试验的事后分析,比较2型糖尿病患者从DPP-4抑制剂转换为口服司美格鲁肽(69例)与继续使用DPP-4抑制剂(77例)24周后β细胞功能的变化。结果显示,司美格鲁肽组HOMA2-β和处置指数(DI)的改善显著优于DPP-4抑制剂组,DI改善与BMI、HbA1c及脂肪肝指数变化相关。

要点

  • 转换为口服司美格鲁肽24周后,HOMA2-β平均变化+10.4 vs DPP-4抑制剂组+0.6(P=.001)。
  • 处置指数(DI)平均变化+0.09 vs DPP-4抑制剂组0.0(P<.001)。
  • 司美格鲁肽剂量≥7 mg/日、脂肪肝指数降低及未使用二甲双胍与DI改善独立相关。

核心结论

  • 与继续使用DPP-4抑制剂相比,转换为口服司美格鲁肽可改善β细胞功能,推测通过肝脏与β细胞间的组织间交互作用介导。

研究设计与样本

  • SWITCH-SEMA2多中心前瞻性随机对照试验的事后分析,受试者为接受DPP-4抑制剂治疗的2型糖尿病患者,随机分为转换为口服司美格鲁肽组或继续DPP-4抑制剂(不调整剂量)组,疗程24周。
  • 共分析146例受试者,其中司美格鲁肽组69例,DPP-4抑制剂组77例。

主要发现

  • 司美格鲁肽组24周后血糖控制、肝酶异常及血脂谱改善。
  • HOMA2-β平均变化司美格鲁肽组+10.4 vs DPP-4抑制剂组+0.6(P=.001)。
  • 处置指数(DI)平均变化司美格鲁肽组+0.09 vs DPP-4抑制剂组0.0(P<.001)。
  • 司美格鲁肽组DI改善与BMI、HbA1c及反映肝脂肪变的脂肪肝指数变化显著相关。
  • 多重线性回归分析显示,司美格鲁肽剂量≥7 mg/日、脂肪肝指数降低及未使用二甲双胍与DI改善独立相关。

关键数值与推荐

  • HOMA2-β平均变化:司美格鲁肽组+10.4 vs DPP-4抑制剂组+0.6(P=.001)。
  • 处置指数(DI)平均变化:司美格鲁肽组+0.09 vs DPP-4抑制剂组0.0(P<.001)。
  • 与DI改善独立相关的因素:司美格鲁肽剂量≥7 mg/日、脂肪肝指数降低、未使用二甲双胍。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Whether continuation of dipeptidyl peptidase-4 inhibitors (DPP-4is) or switching to oral semaglutide is more beneficial for β-cell function is unclear. OBJECTIVE: To assess the efficacy of switching from DPP-4is to oral semaglutide for β-cell function compared with DPP-4i continuation. METHODS: Post hoc analysis of SWITCH-SEMA 2, a multicenter prospective randomized controlled trial on the switch to oral semaglutide vs DPP-4i continuation without dose adjustment for 24 weeks in subjects with type 2 diabetes treated with DPP-4is, was conducted. Changes in markers for glucose metabolism, including homeostatic model assessment (HOMA2) scores and disposition index (DI), were compared between the groups. RESULTS: A total of 146 subjects (semaglutide group, 69; DPP-4i group, 77) were analyzed. In the semaglutide group, glycemic control, liver enzyme deviations, and lipid profiles improved after 24 weeks. Regarding indices for β-cell function, changes in HOMA2-β as well as DI, reflecting the ability of β-cells to compensate for insulin resistance, were significantly higher in the semaglutide group compared with the DPP-4i group (mean change, +10.4 vs +0.6 in HOMA2-β [P = .001] and +0.09 vs 0.0 in DI [P < .001]). Improvement in DI in the semaglutide group was correlated significantly to changes in body mass index (BMI), HbA1c, and fatty liver index reflecting liver steatosis. Multiple linear regression analysis revealed that dose of semaglutide (≥ 7 mg/day), reduction in fatty liver index, and metformin nonuse were independently associated with improvement of DI. CONCLUSION: Switching to oral semaglutide ameliorated β-cell function compared with DPP-4is, presumably via tissue-to-tissue crosstalk between liver and β-cells.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Nomoto H, Furusawa S, Yokoyama H, et al. Improvement of β-Cell Function After Switching From DPP-4 Inhibitors to Oral Semaglutide: SWITCH-SEMA2 Post Hoc Analysis. J Clin Endocrinol Metab. 2025. PMID: 38695547. doi:10.1210/clinem/dgae213

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。